glp-1 with cv benefit Drugs & What They Do Treatment of High-Risk Patients with

In the OASIS-4 trial, people taking the 25 mg oral semaglutide pill lost about 16.6 percent of their body weight over 64 weeks, compared to 2.7 percent with placebo

Effect of hemoglobin A1c reduction or weight reduction on blood pressure in glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor treatment in type 2 diabetes mellitus: a meta-analysis

We break down how they differ in our latest article

Combination therapy is typically reserved for individuals who have not reached their goals with a single medication

The result is a data asset that allows your team to analyze the full obesity patient journey in one place , without the pain of stitching together fragmented data sources